Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Adoptive Cell Therapy (TTRNA-xALT), Dendritic Cell Vaccine (TTRNA-DC), and Hematopoietic Stem Cells in Combination with Pembrolizumab for the Treatment of Relapsed or Progressive Group 3 or 4 Non-SHH/Non-WNT Medulloblastoma, MATCHPOINT Trial

Trial Status: active

This phase I trial tests the safety, side effects, and effectiveness of adoptive cell therapy (ACT) with total tumor messenger ribonucleic acid (mRNA)-pulsed tumor-specific ex vivo-expanded autologous lymphocyte transfer cells (TTRNA-xALT), dendritic cell vaccine, total tumor mRNA-pulsed autologous dendritic cells (TTRNA-DC) and hematopoietic stem cells (HSC) in combination with pembrolizumab in treating patients with group 3 or 4 non-sonic hedgehog (SHH)/non-WNT medulloblastoma that has come back after a period of improvement (relapsed) or that is growing, spreading, or getting worse (progressive). ACT, including TTRNA-xALT, is a type of immunotherapy that uses the body's own immune cells, called T-cells to help fight tumors. Cells from the tumor and immune cells from the patients' blood are used to make a vaccine that may stimulate the T-cells to kill tumor cells and leave the normal cells alone. Before T-cells can become active against tumor cells, they require strong stimulation by dendritic cells, which are also part of the immune system. Although dendritic cells are very strong, the number of them in the body is not high enough to cause a powerful immune response. Therefore, more dendritic cells, such as TTRNA-DC, need to be made in a laboratory with cells collected from the patient's blood. Another type of cells collected during vaccine creation, called peripheral blood stem cells, help the bone marrow recover more quickly after chemotherapy and have been shown to enhance immune responses against the tumor. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Giving ACT with TTRNA-xALT, TTRNA-DC and hematopoietic stem cells in combination with pembrolizumab may be safe, tolerable, and/or effective in treating relapsed or progressive group 3 or 4 non-SHH/non-WNT medulloblastoma.